| Title | Durvalumab plus carboplatin/paclitaxel followed by maintenance durvalumab with or without olaparib as first-line treatment for advanced endometrial cancer: the phase III DUO-E trial / |
|---|---|
| Authors | Westin, Shannon N ; Moore, Kathleen ; Chon, Hye Sook ; Lee, Jung-Yun ; Thomes Pepin, Jessica ; Sundborg, Michael ; Shai, Ayelet ; de la Garza, Joseph ; Nishio, Shin ; Gold, Michael A ; Wang, Ke ; McIntyre, Kristi ; Tillmanns, Todd D ; Blank, Stephanie V ; Liu, Ji-Hong ; McCollum, Michael ; Contreras Mejia, Fernando ; Nishikawa, Tadaaki ; Pennington, Kathryn ; Novak, Zoltan ; De Melo, Andreia Cristina ; Sehouli, Jalid ; Klasa-Mazurkiewicz, Dagmara ; Papadimitriou, Christos ; Gil-Martin, Marta ; Brasiūnienė, Birutė ; Donnelly, Conor ; del Rosario, Paula Michelle ; Liu, Xiaochun ; Van Nieuwenhuysen, Els |
| DOI | 10.1200/JCO.23.02132 |
| Full Text |
|
| Is Part of | Journal of clinical oncology.. American Society of Clinical Oncology. 2024, vol. 42, iss. 3, JCO2302132, p. 283-299.. ISSN 0732-183X. eISSN 1527-7755 |
| Abstract [eng] | Immunotherapy and chemotherapy combinations have shown activity in endometrial cancer, with greater benefit in mismatch repair (MMR)–deficient (dMMR) than MMR-proficient (pMMR) disease. Adding a poly(ADP-ribose) polymerase inhibitor may improve outcomes, especially in pMMR disease. |
| Published | American Society of Clinical Oncology |
| Type | Journal article |
| Language | English |
| Publication date | 2024 |
| CC license |
|